Brief: Prometheus Biosciences Announces Positive Results For PRA023 In Artemis-UC Ph-2 And Apollo-CD Ph-2A Studies

Prometheus Biosciences

07/12/2022 12:25

Dec 7 (Reuters) - Prometheus Biosciences Inc  RXDX.O :
    * PROMETHEUS BIOSCIENCES ANNOUNCES POSITIVE RESULTS FOR
PRA023 IN
BOTH ARTEMIS-UC PHASE 2 AND APOLLO-CD PHASE 2A STUDIES ENABLING
PATHWAY TO BOTH FIRST-IN-CLASS AND BEST-IN-CLASS ANTI-TL1A MAB
    * PROMETHEUS BIOSCIENCES INC - ARTEMIS-UC TRIAL MET PRIMARY
ENDPOINT
    * PROMETHEUS BIOSCIENCES INC - ARTEMIS-UC COHORT 1 MET ALL
RANKED
SECONDARY ENDPOINTS
    * PROMETHEUS BIOSCIENCES INC - APOLLO-CD TRIAL SHOWED 26.0%
ENDOSCOPIC RESPONSE AND 49.1% CLINICAL REMISSION RATES
    * PROMETHEUS BIOSCIENCES INC - PRA023 DEMONSTRATED FAVORABLE
SAFETY AND TOLERABILITY RESULTS ACROSS BOTH STUDIES WITH NO
SAFETY SIGNAL IDENTIFIED
    * PROMETHEUS BIOSCIENCES INC - ARTEMIS-UC COHORT 1 INTERIM
ANALYSIS SUGGESTS A TREND TOWARDS INCREASED PRA023 RESPONSE IN
CDX+ PATIENTS OVER ALL COMERS
    * PROMETHEUS BIOSCIENCES INC - PRA023 SHOWED A SIGNIFICANT
IMPACT
ON MULTIPLE MARKERS OF INFLAMMATION AND FIBROSIS IN APOLLO-CD
    * PROMETHEUS BIOSCIENCES INC - INTENDS TO ADVANCE PRA023
INTO
PHASE 3 STUDIES FOR UC AND CD IN 2023

Source text for Eikon:  ID:nGNX5Z11Gr 
Further company coverage:  RXDX.O 
 ((Reuters.Briefs@thomsonreuters.com;))